GlassScriptPhysician profile
Alexandra Krot
NPI 1164694584
$2,833.72
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $112 · 2021: $725 · 2022: $230 · 2023: $232 · 2024: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $404.62 | 2019-2024 | Reblozyl, Opdivo |
| Alexion Pharmaceuticals, INC. | $363.05 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $347.95 | 2021-2024 | Libtayo |
| Janssen Biotech, INC. | $248.05 | 2021 | |
| Amgen INC. | $210.78 | 2019 | |
| Genentech USA, INC. | $126.04 | 2019 | |
| Pfizer INC. | $125.34 | 2019 | |
| Glaxosmithkline, LLC. | $122.03 | 2021 | |
| Verastem, INC. | $121.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $118.28 | 2019 | |
| Gilead Sciences, INC. | $116.51 | 2019 | |
| Genzyme Corporation | $113.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.79 | 2022 | |
| Dova Pharmaceuticals | $111.29 | 2019 | |
| Astellas Pharma US INC | $109.80 | 2023 | Xtandi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $81.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Krot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.